Homology Medicines (LTS:0T6G) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Homology Medicines LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Homology Medicines's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Homology Medicines's long-term debt to total assets ratio declined from Dec. 2022 (0.12) to Dec. 2023 (0.00). It may suggest that Homology Medicines is progressively becoming less dependent on debt to grow their business.

Homology Medicines LT-Debt-to-Total-Asset Historical Data

The historical data trend for Homology Medicines's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Homology Medicines LT-Debt-to-Total-Asset Chart

Homology Medicines Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.11

0.12

Homology Medicines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.12	0.14	0.16	0.19	-

Homology Medicines LT-Debt-to-Total-Asset Calculation

Homology Medicines's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0	/	84.564
	=	0.00

Homology Medicines's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0	/	84.564
	=

Homology Medicines (LTS:0T6G) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Homology Medicines LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Homology Medicines's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Homology Medicines (LTS:0T6G) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (LTS:0T6G) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

FIXX:USA 35H:Germany

Address

One Patriots Park, Bedford, MA, USA, 01730

Website

https://www.homologymedicines.com

Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Homology Medicines (LTS:0T6G) Headlines

No Headlines